Abstract
P-glycoprotein (Pgp) overexpression is a well-recognized factor in resistance to chemotherapy. Doxorubicin flow cytometry is used to monitor Pgp function in haematological specimens and biopsies from other cancers, and radionuclide imaging with sestamibi has recently shown promise for non-invasive monitoring. In the present study the two methods were directly compared in single-cell suspensions of three variants of the human breast carcinoma cell line MCF7: sensitive MCF7/WT, doxorubicin-selected MCF7/AdrR, and MDR1 -gene-transfected MCF7/BC19 cells with doxorubicin resistance factors of 1, 192, and 14, respectively. Accumulation of sestamibi and mean fluorescence of doxorubicin (5.5 μM) were assessed over 60 min in the presence and absence of Pgp modulators GG918 (0.01 to 0.2 μM) and PSC833 (0.05 to 2.0 μM). Accumulation curves for sestamibi and doxorubicin differed among the cell variants under control conditions, with sestamibi showing a significantly greater difference between WT and resistant cells than doxorubicin. Both GG918 and PSC833 reversed uptake deficits to WT levels for sestamibi in MCF7/BC19 cells and doxorubicin in MCF7/BC19 and MCF7/AdrR cells, but failed to show the same effect for sestamibi in MCF7/AdrR cells (~30% of MCF7/WT level). Thus, both methods clearly distinguished sensitive from resistant MCF7 variants, with the radionuclide method showing greater sensitivity. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ballinger JR, Hua HA, Berry BW, Firby P and Boxen I (1995) 99Tcm-Sestamibi as an agent for imaging P-glycoprotein-mediated multdrug resistance: in vitro and in vivo studies in rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 16: 253–257
Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG and Moore MJ (1996) Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug resistant breast tumor cells. J Nucl Med 37: 1578–1582
Ballinger JR, Muzzammil T and Moore MJ (1997) Technetium-99m furifosmin as an agent for functional imaging of multidrug resistance in tumors. J Nucl Med 38: 1915–1919
Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE and Cowan KH (1986) Overexpression of a novel anionic glutathione-transferase in multidrug resistant human breast cancer cell line. J Biol Chem 261: 15544–15549
Belli JA, Zhang Y and Fritz P (1990) Transfer of adriamycin resistance by fusion of Mr 170,000 P-glycoprotein to the plasma membrane of sensitive cells. Cancer Res 50: 2191–2197
Benderra Z, Trussardi A, Morjani H, Villa AM, Doglia SM and Manfait M (2000) Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein. Eur J Cancer 36: 428–434
Bradley G, Juranka PF and Ling V (1988) Mechanism of drug resistance. Biochem Biophys Acta 948: 87–128
Broxterman HJ, Sonnenveld P, Feller N, Ossenkoppele GJ, Wahrer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Lowenberg B and Schuurhuis GJ (1996) Quality control of multidrug resistance assays in adult leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 87: 4809–4816
Brueninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA and Kruh GD (1995) Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 55: 5342–5347
Cayre A, Moins N, Finat-Duclos F, Maublant J and Verrelle P (1999) Comparative 99mTc-sestamibi and 3H-daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agents. J Nucl Med 40: 672–676
Chan HSL, Bradley G, Thorner P, Haddad G, Gallie BL and Ling V (1988) Methods in laboratory investigation: a sensitive method for immunohistochemical detection of P-glycoprotein in multidrug resistant human ovarian carcinoma cell lines. Lab Invest 59: 870–875
Chiu ML, Kronauge JF and Piwnica-Worms D (1990) Effects of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxy isobutyl isonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med 31: 1646–1653
Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan MV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654
Crankshaw CL, Marmion M, Luker GD, Vallabhaneni R, Dahlheimer J, Burleigh BD, Webb E, Deutsch KF and Piwnica-Worms D (1998) Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDRI) P-glycoprotein. J Nucl Med 39: 77–86
Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF and Starling JJ (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56: 4171–4179
Davis S, Weiss MJ, Wong JR, Lampidis TJ and Chen LB (1985) Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 25: 13844–13850
Del Vecchio S, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G, Thomas R, Cerra M, D’Aiuto G, Tsuruo T and Salvatore M (1997) In vivo detection of multidrug resistance (MDR-1) phenotype by technetium-99m-sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 24: 150–159
Del Vecchio S, Ciarmiello A and Salvatore M (1999) Clinical imaging of multidrug resistance in cancer. Q J Nucl Med 43: 125–131
Fairchild CR, Moscow JA, O’Brien EE and Cowan KH (1990) Multidrug resistance in cells transfected with human gene encoding a variant of P-glycoprotein and glutathione-S-transferase-π. Mol Pharmacol 37: 801–809
Ford JM and Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155–199
Hendrikse NH, Franssen EJF, van der Graaf WTA, Meijer C, Piers DA, Vaalburg W and de Vries EGE (1998) 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 77: 353–358
Hendrikse NH, Franssen EJF, van der Graaf WTA, Vaalburg W and de Vries EGE (1999) Visualization of multidrug resistance in vivo. Eur J Nucl Med 26: 283–293
Hyafil F, Vergely C, Vignaud PD and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF 120918, an acridonecarboxamide derivative. Cancer Res 53: 4595–4602
Kessel D, Beck WT, Kukuruga D and Schulz V (1991) Characterization of multidrug resistance by fluorescent dyes. Cancer Res 51: 4665–4670
Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, Ishibashi K, Kodama M, Iwahashi M, Arima T and Akiyama S-I (1990) Expression of the MDR transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 66: 868–873
Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W and Garnier-Suillerot A (1998) Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol Pharmacol 53: 141–147
Muzzammil T, Ballinger JR and Moore MJ (1999) 99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer. Nucl Med Commun 20: 115–122
Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA and Croop JM (1993) Functional imaging of multidrug resistance P-glycoprotein with an organotechnetium complex. Cancer Res 53: 977–984
Schneider E, Horton JK, Yang C-H, Nakagawa M and Cowan KH (1994) Multidrug resistance associated protein gene overexpression and reduced drug sensitivity to topoisomerase-II in human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54: 152–158
Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JPA, Eekman CA, Kuiper CM, Feller N, van Heijningen THM, Klumper E, Pieters R, Lankelma J and Pinedo HM (1995) Functional multidrug resistance phenotype associated with combined overexpression of Pgp/ MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1: 81–93
Sommers CL, Byers SW, Thompson EW, Torri JA and Gelmann EP (1994) Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31: 325–335
Takanashi S and Bachur NR (1976) Adriamycin metabolism in man: evidence from urinary metabolites. Drug Metab Dispos 4: 79–88
Trock BJ, Leonessa F and Clarke R (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89: 917–931
Tunggal JK, Ballinger JR and Tannock IF (1999) The influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents. Int J Cancer 81: 741–747
Twentyman PR (1988) Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins. Br J Cancer 57: 254–258
Vergote J, Moretti JL, de Vries EGE and Garnier-Suillerot A (1998) Comparison of the kinetics of active efflux of99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur J Biochem 252: 140–146
Xie X-Y, Robb D, Chow S and Hedley DW (1995) Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia 9: 1882–1887
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Muzzammil, T., Moore, M., Hedley, D. et al. Comparison of 99mTc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function. Br J Cancer 84, 367–373 (2001). https://doi.org/10.1054/bjoc.2000.1621
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1621
Keywords
This article is cited by
-
Predicting Early Chemotherapy Response with Technetium-99m Methoxyisobutylisonitrile SPECT/CT in Advanced Non-Small Cell Lung Cancer
Molecular Imaging and Biology (2010)
-
Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties
Cancer Chemotherapy and Pharmacology (2006)
-
To use MIBI or not to use MIBI? That is the question when assessing tumour cells
European Journal of Nuclear Medicine and Molecular Imaging (2005)